LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (NASDAQ: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the February 16, 2016, lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the complaint, the Company issued materially false and misleading statements to investors and/or failed to disclose that: (1) the CEO of KaloBios was engaged in a scheme involving the illegal use of stock from Retrophin, Inc. to pay off debts associated with other unrelated business ventures; and (2) the discovery and revelation of that scheme would likely undermine KaloBios’ operations and prospects.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.